Qin, Wanru http://orcid.org/0000-0002-3608-3675
Xu, Guangchao
Tai, Phillip W. L. http://orcid.org/0000-0001-7409-8344
Wang, Chunmei
Luo, Li
Li, Chengjian
Hu, Xun
Xue, Jianxin
Lu, You http://orcid.org/0000-0003-1671-1408
Zhou, Qiao http://orcid.org/0000-0002-5133-1438
Wei, Qiang
Wen, Tianfu
Hu, Jiankun
Xiao, Yuanyuan
Yang, Li
Li, Weimin
Flotte, Terence R. http://orcid.org/0000-0002-8255-0588
Wei, Yuquan http://orcid.org/0000-0002-6211-3217
Gao, Guangping http://orcid.org/0000-0003-0097-9012
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Institute of Neurological Disorders and Stroke (R01NS076991)
U.S. Department of Health & Human Services | NIH | National Heart, Lung, and Blood Institute (P01HL59407, P01HL131471)
Division of Intramural Research, National Institute of Allergy and Infectious Diseases (R01AI100263)
U.S. Department of Health & Human Services | NIH | National Heart, Lung, and Blood Institute
Article History
Received: 13 December 2020
Revised: 28 January 2021
Accepted: 18 February 2021
First Online: 29 March 2021
Compliance with ethical standards
:
: GG work has been funded by the NIH, and is a scientific co-founder of Voyager Therapeutics and Aspa Therapeutics, and holds equity in these companies. GG is an inventor on patents with potential royalties licensed to Voyager Therapeutics, Aspa Therapeutics, and other biopharmaceutical companies. The remaining authors declare no competing interests.